ライフサイエンスコーパス: cirrhosis

1 liver disease (primary liver cancer [LC] and cirrhosis).

2 ost frequent cause of portal hypertension is cirrhosis.

3 identified in this study, conferred risk for cirrhosis.

4 d survival among patients with decompensated cirrhosis.

5 inclusions, causing lung emphysema and liver cirrhosis.

6 No patients had known cirrhosis.

7 ith NAFLD outside the context of established cirrhosis.

8 ignificant liver fibrosis including 12% with cirrhosis.

9 s that affect development of alcohol-related cirrhosis.

10 se, but some had immunosuppression and liver cirrhosis.

11 (PY) and 1.5 to 2.3/100 PY in patients with cirrhosis.

12 al infections in patients with decompensated cirrhosis.

13 ess the applicability of ordinal outcomes in cirrhosis.

14 s, autoimmune hepatitis, and primary biliary cirrhosis.

15 thresholds for surveillance in patients with cirrhosis.

16 enced patients, including those with GT3 and cirrhosis.

17 ed with the frail phenotype in patients with cirrhosis.

18 ns to increase surveillance in patients with cirrhosis.

19 ed fibrosis; and ALR-H-KO mice progressed to cirrhosis.

20 ality of care and outcomes for patients with cirrhosis.

21 oholic steatohepatitis (NASH) and subsequent cirrhosis.

22 arkers in patients with advanced HCV-related cirrhosis.

23 significantly correlated with liver fibrosis/cirrhosis.

24 e to lower proportion of PUHSC patients with cirrhosis.

25 eatments to patients with coexisting AUD and cirrhosis.

26 collected prospectively in 182 patients with cirrhosis.

27 ative mortality predictions in patients with cirrhosis.

28 ey injury (AKI) is known in patients without cirrhosis.

29 isease (GRAIL) developed among patients with cirrhosis.

30 h as mortality, hepatocellular carcinoma, or cirrhosis.

31 ith advanced hepatitis C virus (HCV)-related cirrhosis.

32 significantly reduced in patients with NASH-cirrhosis.

33 patients with NASH and bridging fibrosis or cirrhosis.

34 resident, inflammatory PMs in patients with cirrhosis.

35 g inflammation and fibrogenesis that lead to cirrhosis.

36 compared to liver biopsy (LB) in diagnosing cirrhosis.

37 and exclusively in those with pre-treatment cirrhosis.

38 of predicting complications in patients with cirrhosis.

39 ip with outcome in acutely ill patients with cirrhosis.

40 the different complications of patients with cirrhosis.

41 f postparacentesis bleeding in patients with cirrhosis.

42 e to the development of AKI in patients with cirrhosis.

43 45.4% UMHS and 16.2% PUHSC patients had cirrhosis.

44 utes to the frail phenotype in patients with cirrhosis.

45 patients with non-invasively diagnosed NAFLD-cirrhosis.

46 t-term mortality in patients with underlying cirrhosis.

47 was alcohol (50.5%), followed by cryptogenic cirrhosis (14.5%), hepatitis C (13.4%), and non-alcoholi

48 es samples of 66 patients with decompensated cirrhosis (19 with SBP) and analyzed them by flow cytome

49 udy consisted of 2,974 NAFLD cases (518 with cirrhosis, 2,456 without cirrhosis) and 29,474 matched c

50 ion (45%), solid organ transplant (26%), and cirrhosis (22%).

51 Among 354 Mayo Clinic patients with NASH cirrhosis, 253 (71%) had diabetes and 145 (41%) were mal

52 rowth was more common in nonviral than viral cirrhosis (50.9% versus 32.1%), particularly in patients

53 A total of 193 patients with cirrhosis (62% with ascites and/or hepatic encephalopath

54 te cohort of 111 patients with decompensated cirrhosis (67 with SBP) and quantified the soluble form

55 d (95% male [80% gay and bisexual men,], 13% cirrhosis, 80% history of injecting drug use [39% curren

56 rocedures were performed among patients with cirrhosis; 92% were esophagogastroduodenoscopies.

57 dian age 49.5 years, 76.5% males, 48.3% with cirrhosis, 98.3% on antiretroviral therapy, median CD4+

58 erved in persons with more advanced fibrosis/cirrhosis (absolute difference 2.9 for fibrosis severity

59 LC and cirrhosis accounted for 38.3% and 61.7%, respectively, o

60 elevated ALT had a higher risk of developing cirrhosis (adjusted hazard ratio: 3.37; 95% CI: 2.34-4.8

61 risk of hospital mortality, particularly for cirrhosis (adjusted odds ratio [aOR], 2.67; 95% confiden

62 ociated with reduced risk of alcohol-related cirrhosis (adjusted odds ratio, 0.76; P=.0027); converse

63 ed with an increased risk of alcohol-related cirrhosis (adjusted odds ratio, 1.30; P=.020).

64 may be a reasonable target in patients with cirrhosis admitted to the ICU.

65 plant registration (aHR = 0.580.971.61), and cirrhosis (aHR = 0.730.921.16).

66 In patients with decompensated cirrhosis, AKI is associated with both hypocoagulable an

67 d that even after accounting for etiology of cirrhosis, alpha-fetoprotein (AFP) at liver transplant,

68 lications (liver transplant registration and cirrhosis) among HCV+ recipients using logistic and Cox

69 anish general population, including 497 with cirrhosis and 113 with hepatocellular carcinoma.

70 iobank Japan including 3554 individuals with cirrhosis and 343,826 controls).

71 a high short-term mortality in patients with cirrhosis and acute on chronic liver failure (ACLF).

72 e observational study in patients with liver cirrhosis and an indication for fluoroquinolone-based pr

73 lected data on 105 consecutive patients with cirrhosis and aortic stenosis who underwent TAVR (n = 55

74 ated, and highly functional in decompensated cirrhosis and are further enriched in SBP.

75 in thrombosis, and bleeding in a cohort with cirrhosis and atrial fibrillation (AF).

76 ery may be a viable option for patients with cirrhosis and extreme obesity.

77 ith plasma markers of liver disease and with cirrhosis and HCC in 110,761 individuals from Copenhagen

78 tional metabolic trait increased the risk of cirrhosis and HCC in patients with NAFLD.

79 ive cohort study of patients aged 50-69 with cirrhosis and HCC in the Veterans Health Administration

80 ith the risks for developing alcohol-related cirrhosis and HCC were determined using logistic regress

81 ipants, including 1,031 with alcohol-related cirrhosis and HCC, 1,653 with alcohol-related cirrhosis

82 iants and the development of alcohol-related cirrhosis and HCC.

83 ecific hazard models to evaluate the risk of cirrhosis and HCC.

84 18 to December 2019, participants with liver cirrhosis and healthy control participants underwent hep

85 oss-sectional study, including patients with cirrhosis and hepatitis B and C, from 2015 to 2017 who u

86 We examined incidence rates for cirrhosis and hepatocellular carcinoma (HCC) and conduct

87 Chronic liver injury is a risk factor for cirrhosis and hepatocellular carcinoma (HCC).

88 es severe liver disease which often leads to cirrhosis and hepatocellular carcinoma (HCC).

89 For each TA-allele, the risk of cirrhosis and hepatocellular carcinoma was reduced by 15

90 ASH and prevent its complications, including cirrhosis and hepatocellular carcinoma, pharmacological

91 mpacts short-term mortality in patients with cirrhosis and high MELD-Na.

92 lure, develops in up to 50% of patients with cirrhosis and is a major determinant of survival.

93 ation of large-volume (>5 L) paracentesis in cirrhosis and is reduced with albumin infusion.

94 to more severe pathologic conditions such as cirrhosis and liver cancer.

95 r disease (ALD) accounts for the majority of cirrhosis and liver-related deaths worldwide.

96 mining urgency of LT and mortality models in cirrhosis and LT waitlisting, especially with an ageing

97 ass II DSA after LT is associated with graft cirrhosis and may indicate a higher risk to develop graf

98 ophages were increased compared to alcoholic cirrhosis and monocytes were found to be located around

99 last viral load after VLVL was low, compared cirrhosis and mortality in persons with and without VLVL

100 ures of NAFLD-associated HCC patients in the cirrhosis and non-cirrhosis setting were also identified

101 Severity of cirrhosis and platelet count were comparable between gro

102 NS5A-inhibitor experienced participants with cirrhosis and portal hypertension, prior liver transplan

103 bnormalities in the kidneys of patients with cirrhosis and renal dysfunction has prompted the functio

104 nd increased concentrations in patients with cirrhosis and SBP indicate reduced odds of surviving for

105 ur findings using data from 71 patients with cirrhosis and SBP.

106 cement (SAVR) is preferred for patients with cirrhosis and severe aortic stenosis.

107 robiome was associated with complications of cirrhosis and survival.

108 Contemporary outcomes of pregnant women with cirrhosis and their infants, as well as liver-related co

109 ents with alcohol-associated or NASH-related cirrhosis and those not followed in subspecialty gastroe

110 sease confers up to a 12-fold higher risk of cirrhosis and up to a 29-fold higher risk of HCC in indi

111 ification of Disease, Ninth Edition codes of cirrhosis and without a history of hepatocellular carcin

112 FLD cases (518 with cirrhosis, 2,456 without cirrhosis) and 29,474 matched controls.

113 Of the 271,906 patients, 22,794 developed cirrhosis, and 253 developed HCC during a mean of 9 year

114 45.4% and specificity of 95% in diagnosis of cirrhosis, and cut-off of 1 had sensitivity of 75.9% and

115 ascites of patients with decompensated liver cirrhosis, and focus especially on MAIT cells.

116 ansmitted diseases, decompensated cirrhosis, cirrhosis, and hepatitis C virus compared to patients wi

117 liver disease, including bridging fibrosis, cirrhosis, and hepatocellular carcinoma, in this populat

118 ive factor of chronic viral hepatitis, liver cirrhosis, and hepatocellular carcinoma.

119 y readmission, age > 64 years, non-alcoholic cirrhosis, and length of stay > 10 days were significant

120 osis to nonalcoholic steatohepatitis (NASH), cirrhosis, and liver cancer.

121 ophages were increased compared to alcoholic cirrhosis, and monocytes were found to be located around

122 ted with chronic viral infections, alcoholic cirrhosis, and nonalcoholic fatty liver disease, genetic

123 liver disease 15-34, without primary biliary cirrhosis, and not on life support before transplant.

124 patients (abnormal hepatic function, hepatic cirrhosis, and pneumonitis).

125 Patients with NASH, cirrhosis, and portal hypertension (hepatic venous press

126 a phase 2b study of 162 patients with NASH, cirrhosis, and portal hypertension, 1 year of biweekly i

127 efficacy of GR-MD-02 in patients with NASH, cirrhosis, and portal hypertension.

128 ), use of opioids (aOR, 2.78; P = .007), and cirrhosis (aOR 5.49; P = .008) were independently associ

129 Patients with cirrhosis are at increased risk of postoperative mortali

130 Patients with cirrhosis are at risk of AKI owing to a wide range of fa

131 complications among endoscopic procedures in cirrhosis are rare overall.

132 and angiogenesis with the severity of liver cirrhosis (assessed by the Child-Pugh-Turcotte score, CT

133 613567:TA attenuated the risk for developing cirrhosis associated with PNPLA3 rs738409:G in both men

134 As part of the cirrhosis-associated immune dysfunction, mucosal-associa

135 ere better than or equal to LB at diagnosing cirrhosis at 5% prevalence.

136 r poor for patients with HDV viremia without cirrhosis at baseline, but it was nevertheless more beni

137 Ten patients not diagnosed with cirrhosis at enrollment but median APRI >= 2.0 developed

138 analyses of serum samples from patients with cirrhosis at multiple centers to determine whether metab

139 al microbiomes of patients hospitalized with cirrhosis at multiple centers, we associated metabolites

140 Among patients with cirrhosis awaiting liver transplantation, prediction of

141 Adults with cirrhosis awaiting LT without hepatocellular carcinoma a

142 ught to compare trends in the development of cirrhosis between patients with NAFLD who underwent bari

143 geneity is in part attributable to age, sex, cirrhosis, body mass index, and/or type of antiretrovira

144 ltidisciplinary teams managing patients with cirrhosis, both inpatient and outpatient.

145 All groups received high quality cirrhosis care.

146 QALY); cases identified, treated, and cured; cirrhosis cases avoided; incremental cost-effectiveness

147 HBV was found in 69.5% of HCC and 47.2% of cirrhosis cases, and HCV in 6.4% and 3.7% respectively.

148 ontrolled study with 106 obese patients with cirrhosis (cases) and 317 age, sex, body mass index-, an

149 In livers of patients with PSC cirrhosis, CD14(hi) CD16(int) and CD14(lo) CD16(hi) mono

150 In livers of patients with PSC cirrhosis, CD14(hi)CD16(int) and CD14(lo)CD16(hi) monocy

151 l from controls (Ctrl-Hum) and patients with cirrhosis (Cirr-Hum).

152 sexually transmitted diseases, decompensated cirrhosis, cirrhosis, and hepatitis C virus compared to

153 ersistently normal ALT are at lower risk for cirrhosis compared to those with steatosis and elevated

154 ormation about nursing care of patients with cirrhosis compared with other chronic diseases.

155 nd neuronal activation in mice regardless of cirrhosis compared with those from healthy humans.

156 ere liver disease outcomes (defined as liver cirrhosis, complications of cirrhosis, or liver-related

157 pe of surgery-matched obese patients without cirrhosis (controls) who underwent bariatric surgery.

158 In the validation set, HEPAVIR and HIV cirrhosis criteria spared 54% and 48.7% of EGDs, while m

159 platelets >110 000/muL and LSM <30 kPa (HIV cirrhosis criteria), with 34.6% of EGDs spared and 0% EV

160 d-Pugh-Turcotte score, CTP) and Child-Pugh B cirrhosis (CTP 7-9) in patients with advanced hepatitis

161 rkers to detect the presence of Child-Pugh B cirrhosis (CTP 7-9) were IP-10 (p-value= 0.008) and IL-6

162 ction) were related to the severity of liver cirrhosis (CTP score), mainly IP-10 and IL-6, which disc

163 61.7%, respectively, of liver deaths (LC and cirrhosis deaths were related to HBV [39% and 29%], HCV

164 6.0% increase in LC deaths; 8.7% increase in cirrhosis deaths).

165 es, the use of ordinal outcomes in trials of cirrhosis decompensation may provide more power and thus

166 considered 509 consecutive patients with HCV cirrhosis (defined histologically or when liver stiffnes

167 k of EE in candidemia included endocarditis, cirrhosis, diabetes with chronic complications, intraven

168 ve multicenter cohort study of patients with cirrhosis diagnosed with HCC from 2008 to 2017 at six US

169 ed especially well in patients with specific cirrhosis diagnoses (C-statistic = 0.84, 95% CI 0.81-0.8

170 d other primary comorbidities at the time of cirrhosis diagnosis.

171 ol participants, the participants with liver cirrhosis displayed reduced longitudinal strain and elev

172 d to coordinate care for pregnant women with cirrhosis during pregnancy and postpartum to optimize ou

173 stigated the gut microbiome in patients with cirrhosis encompassing the whole spectrum of disease (co

174 Adults with cirrhosis evaluated for their first LT in 2012 were foll

175 Mean age at cirrhosis evaluation was 62.

176 al hemorrhage in patients with decompensated cirrhosis (first section); we reviewed the use of interv

177 epatitis C viral (HCV) infection and without cirrhosis, glecaprevir/pibrentasvir for 8 weeks is recom

178 fter the surgery, there were 3 deaths in the cirrhosis group and 1 in the control group (2.8% vs 0.6%

179 At 90 days there was 1 death in the cirrhosis group but no additional deaths in the control

180 In the cirrhosis group, there was no death in the first 30 days

181 Cirrhosis, >1 nodule, and AFP >100 ng/mL were identified

182 LPMs vs SPMs from patients with cirrhosis had different transcriptomes; we identified mo

183 oinfected patients with advanced HCV-related cirrhosis had near-equivalent values of plasma biomarker

184 Risk scoring for patients with cirrhosis has evolved greatly over the past several deca

185 role of nurses in the care of patients with cirrhosis has not been sufficiently emphasized and there

186 It is uncertain if the incidence of cirrhosis has previously been underestimated or if an ac

187 a had 1.8-fold higher risk of progression to cirrhosis/HCC (hazard ratio [HR] = 1.8, 95% confidence i

188 ority do not develop advanced liver disease: cirrhosis, hepatic decompensation, or hepatocellular car

189 ility in mortality rates from liver disease (cirrhosis + hepatocellular carcinoma), but data are lack

190 ith significant morbidity and mortality from cirrhosis, hepatocellular carcinoma, solid organ maligna

191 001), substantial in patients with alcoholic cirrhosis (HR, 1.007; P < 0.001) and rather weak in pati

192 strong in patients with hepatitis C-related cirrhosis (HR, 1.013; P < 0.001), substantial in patient

193 this organization, as occurs in fibrosis and cirrhosis, impairs liver function and leads to disease.

194 to identify risk factors for liver fibrosis/cirrhosis in a cohort of Greek HIV-infected patients.

195 sis are associated with an increased risk of cirrhosis in a general population, but their predictive

196 orporating an LB or NIT strategy to diagnose cirrhosis in a hypothetical cohort of 1,000 asymptomatic

197 ntly associated with NAFLD and NAFLD-related cirrhosis in a multiethnic population.

198 metabolic disease and obesity, progresses to cirrhosis in approximately 20% of cases, and is associat

199 to detect non-alcoholic steatohepatitis and cirrhosis in biopsied samples of human liver tissue.

200 ty (the Pi*MZ genotype) is a risk factor for cirrhosis in individuals with liver disease.

201 orphisms that affect risk of alcohol-related cirrhosis in opposite directions: the minor A allele in

202 ignificantly associated with alcohol-related cirrhosis in phase 2 validation cohort, at a false disco

203 Background Cardiac involvement in liver cirrhosis in the absence of underlying cardiac disease i

204 d to describe the incidence and aetiology of cirrhosis in the Halland region from 2011 to 2018, and t

205 ure is critically important in patients with cirrhosis in the ICU, however, there is limited data to

206 ignificantly associated with alcohol-related cirrhosis in the phase 1 validation cohort; 6 of these 9

207 Variants associated with alcohol-related cirrhosis in the validation at a false discovery rate of

208 ve cohort study of patients with compensated cirrhosis in the Veterans Health Administration database

209 R3B and LYPLAL1) and gene variants linked to cirrhosis (in HFE and SERPINA1).

210 persons with baseline Fibrosis-4 1.46-3.25, cirrhosis incidence/1000 patient-years was 49.3 among he

211 Although age-standardized incidence rate for cirrhosis increased from 66.0 to 66.3, ASDR and age-stan

212 species is a complication for patients with cirrhosis, indwelling catheters, or undergoing peritonea

213 Cirrhosis is a complex disease that is associated with d

214 In a population-based study, we found that cirrhosis is an independent risk factor for adverse peri

215 Cirrhosis is associated with changes in gut microbiome c

216 ialty gastroenterology or hepatology care in cirrhosis is associated with higher adherence to guideli

217 D-associated HCC may arise in the absence of cirrhosis, is often diagnosed at advanced stages, and is

218 virus infection with a greater risk of liver cirrhosis (LC) and hepatocellular carcinoma (HCC).

219 In the setting of liver cirrhosis (LC), profound hemostatic changes occur, which

220 alcohol use disorder (AUD) in patients with cirrhosis, little is known about AUD treatment patterns

221 nfected patients may reflect improvements in cirrhosis management and/or persistent barriers to LT.

222 g HCV infected persons before development of cirrhosis may reduce risk of HCC.

223 riteria was observed in 66% of patients with cirrhosis, more so in those with previous AKI episodes a

224 Median age was 58, 82% were male, 78% had cirrhosis, most with portal hypertension (61%, n=46/76),

225 trols (n = 24) and patients with compensated cirrhosis (n = 11).

226 olled nonelective hospitalized patients with cirrhosis (n = 726).

227 ASDR for cirrhosis-NAFLD increased (APC = 0.29% [0.01%-0.59%]) bu

228 ine hemostasis in patients with stable liver cirrhosis (Non-ACLF) and in acute-on-chronic liver failu

229 Neither cirrhosis nor incidental diagnosis were associated with

230 with splenomegaly and symptoms of the liver cirrhosis occurred (thrombocytopenia, collateral venous

231 ciated with a lower risk for developing both cirrhosis (odds ratio [OR], 0.79; 95% confidence interva

232 ociated with significantly increased risk of cirrhosis (odds ratio, 2.26; P < .001) and related comor

233 , 3, 4, and 5 or 6 had odds ratios (ORs) for cirrhosis of 1.6 (95% confidence interval [CI], 1.3, 1.9

234 lead to progressive fibrosis and eventually cirrhosis of the liver.

235 omatic in the initial stages and can lead to cirrhosis of the liver.

236 We ascertained incident cases of cirrhosis or complications by linking Swedish health dat

237 ve or combined indicators on time to develop cirrhosis or HCC or a composite endpoint of both.

238 onal Classification of Diseases (ICD-10) for cirrhosis or its complications.

239 er tissue from patients with AH or alcoholic cirrhosis or normal liver tissue from hepatic resection.

240 ciated with an increased risk for developing cirrhosis (OR, 1.70; 95% CI, 1.54-1.88; P = 1.52 x 10(-2

241 defined as liver cirrhosis, complications of cirrhosis, or liver-related death) or advanced fibrosis/

242 sterol and NAFLD with cirrhosis than without cirrhosis (P heterogeneity <=0.014).

243 Cirrhosis patients are higher risk for sedation, yet lim

244 More specifically, in decompensated-cirrhosis patients, "high-risk" grafts did not appear to

245 In patients with primary biliary cholangitis/cirrhosis (PBC), hepatic levels of miR-210 and KLF4 were

246 Cirrhosis prevalence was modeled at 5%, 20%, and 50%.

247 is with equivalence to LB at 5%, 20% and 50% cirrhosis prevalence were; 89% and 88%, 94% and 85%, and

248 LPMs from patients with cirrhosis produced more inflammatory cytokines than LPMs

249 potential inclusion of chloride into future cirrhosis prognostic scores.

250 al comorbidities, insurance and adherence to cirrhosis quality care indicators were recorded to deter

251 the use and impact of NSBB in patients with cirrhosis referred for liver transplantation.

252 actice providers (APPs) can expand access to cirrhosis-related care, their impact on the quality of c

253 one half of acute care hospitalizations for cirrhosis-related complications result in inpatient spec

254 , a common anatomical site for infections in cirrhosis, remain elusive.

255 r Cancer (BCLC) B and C, and the presence of cirrhosis, respectively.

256 al microbial colonization from patients with cirrhosis results in higher degrees of neuroinflammation

257 biopsy-proven NASH and bridging fibrosis or cirrhosis seen at Indiana University Medical Center betw

258 All patients with the diagnosis of NASH cirrhosis seen at Mayo Clinic Rochester between January

259 ciated HCC patients in the cirrhosis and non-cirrhosis setting were also identified.

260 nd mortality was related with comorbidities, cirrhosis severity, and complexity of surgery.

261 rsistently low MELD-Na scores, patients with cirrhosis still experience high rates of liver-related m

262 red to have more advanced fibrosis including cirrhosis suggesting a potential synergistic effect of c

263 te parenchymal renal injury in patients with cirrhosis, suggesting that concurrent mechanisms, includ

264 level data to derive and internally validate cirrhosis surgical risk models.

265 ween red meat and cholesterol and NAFLD with cirrhosis than without cirrhosis (P heterogeneity <=0.01

266 icularly in patients with Child-Pugh Class B cirrhosis the new score showed a good ability to identif

267 analysis of patients with Child-Pugh Class B cirrhosis, the CreLiMAx risk score remained the only par

268 e current consensus is that in patients with cirrhosis, the hemostasis is shifted toward a procoagula

269 Among the 105 patients with cirrhosis, the median Society of Thoracic Surgeons score

270 nflammation and liver damage, culminating in cirrhosis, the penultimate step in the progression towar

271 (ACLF) is the most severe clinical stage of cirrhosis, there is lack of information about gut microb

272 tion in patients with and without underlying cirrhosis (third section).

273 mes following TAVR and SAVR in patients with cirrhosis to inform the preferred intervention.

274 ncing of 54 liver nodules from patients with cirrhosis to quantify aneuploidy, a possible outcome of

275 tify new genetic variants that predispose to cirrhosis, to test whether such variants, aggregated int

276 Patients with liver cirrhosis typically exhibit abnormal coagulation paramet

277 SVR12 in participants with GT3 and cirrhosis was 90%.

278 Cirrhosis was present in 6.6% of patients overall and 11

279 Liver function of 113 patients with liver cirrhosis was prospectively investigated.

280 Cirrhosis was strongly associated with HCC risk (adjuste

281 ysis for end-stage renal disease but without cirrhosis were included as controls.

282 , chronic obstructive pulmonary disease, and cirrhosis were statistically more likely to have a DNR o

283 y CHC patients (17 chronic hepatitis, and 63 cirrhosis) were enrolled.

284 A followed by inflammatory bowel disease and cirrhosis, whereas other liver disease, including biliar

285 iomarkers to stratify NAFLD patients without cirrhosis who are at risk for HCC.

286 spective cohort study included Veterans with cirrhosis who received Veterans Health Administration ca

287 Included were 300 adult patients with cirrhosis who underwent outpatient physical frailty test

288 ts with confirmed diagnosis of decompensated cirrhosis who were admitted to the ICU between March 201

289 A single-center cohort of patients with cirrhosis, who were referred and evaluated for liver tra

290 he final cohort included 2,694 veterans with cirrhosis with AF (n = 1,694 and n = 704 in the warfarin

291 fibrinolysis) in patients with decompensated cirrhosis with and without AKI.

292 ving from the two models that could diagnose cirrhosis with at least equal mortality to LB was termed

293 lytic phenotype in acutely ill patients with cirrhosis with baseline hypofibrinolysis associated with

294 imum sensitivity and specificity to diagnose cirrhosis with equivalence to LB at 5%, 20% and 50% cirr

295 ostic accuracy criteria for NITs to diagnose cirrhosis with equivalence to LB in terms of mortality.

296 eled as risk by age 75 years, probability of cirrhosis with extreme polygenic risk was 13.7%, 20.1%,

297 bile duct ligation model was used to develop cirrhosis with HE in rats.

298 ollected from 35 patients with decompensated cirrhosis, with or without spontaneous bacterial periton

299 irrhosis and HCC, 1,653 with alcohol-related cirrhosis without HCC, 2,588 alcohol misusers with no li

300 virus (HCV) infection is a leading cause of cirrhosis worldwide and kills more Americans than 59 oth